Ora Clinical Hires 11 Roles to Guard Its Zero-Phase-3-Failure Record

The Only CRO That Never Missed a Phase 3

Ora Clinical has never failed to reproduce a Phase 2 result in Phase 3 across 22 drug approval programs. That half-century track record — built on a single organ, the eye — now drives a targeted hiring push: multiple open roles concentrated in clinical operations and regulatory compliance, the functions that translate ophthalmic science into approvable trials.

Founded in 1974 by Harvard ophthalmologist Mark Abelson, the company has supported 22 approved ocular allergy products and more than 85 product approvals across over 3,000 ophthalmic clinical projects. The current approval count stands at 52, covering dry eye, allergy, glaucoma, contact lenses, and diagnostic imaging. With 201–500 employees and $77.6 million in revenue, Ora operates as a full-service ophthalmic CRO but resists the label. "The CRO as a word applies to only a part of Ora," Stuart Abelson said in an OIS Podcast interview, describing a model that spans pre-clinical models, unique methodologies, integrated data solutions, and global regulatory strategy under one roof. The medical device business, he added, "is roaring."

Geographically, the bulk of staff sits in the Boston area where the company was founded. A London office of roughly 30 covers Europe; about 20 employees in China plus activity in Australia handle Asia-Pacific. Leadership reflects the hybrid scientific-commercial model: Paul Colvin serves as CEO; Gustavo De Moraes, MD, PhD, MPH, is chief medical officer; Hal Patterson runs CMC and regulatory as senior vice president; Marcin Ernst leads Europe; Tim Neathery serves as chief people officer; and Henry Gerock is general counsel. Abelson remains the scientific anchor.

The open roles map to the operational backbone that keeps this engine running. Clinical operations — the function that designs, launches, and monitors trials across Ora's global site network — sits at the center. Regulatory compliance roles support Patterson's group, which navigates FDA, EMA, and Asian agency pathways for both drugs and devices. The company's "home grow" philosophy, built on an internal training program, means these hires are expected to absorb Ora's proprietary methodologies — challenge models, imaging endpoints, surgical device protocols — rather than arrive with them pre-installed.

That distinction matters. General biotech CROs hire for therapeutic breadth; Ora hires for ophthalmic depth.

Why the Market Is Pulling Ora Into a Hiring Cycle

The ophthalmology drug market is not merely growing — it is restructuring around modalities and delivery challenges that demand specialized trial execution.

Market.us data shows $85.6 billion by 2033; the spread reflects different segmentation assumptions, but the direction is unanimous — and the North America share, at 44–61% of revenue depending on the source, concentrates opportunity in Ora's home region.

Demographics provide the baseline. The World Health Organization estimates 2.2 billion people globally have vision impairment, with 1 billion cases preventable or untreated. WHO projects a threefold increase by 2050, driven by aging populations — by 2020, adults over 60 already outnumbered children under five. Age-related macular degeneration, glaucoma, diabetic macular edema, and dry eye disease scale directly with that curve. Retinal disorders alone accounted for $8.4 billion in 2023. Anti-VEGF agents hold 38% of the market, and the monoclonal antibody and fusion protein segment captured 84% of revenue share in 2024.

The pipeline is shifting. Gene therapies with novel vectors, bispecific and trispecific antibodies, multivalent antibodies, fusion proteins, and stem cell therapies are in development for both rare conditions, such as retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis, and prevalent ones like AMD and geographic atrophy. Luxturna's approval for retinitis pigmentosa and faricimab's recent approval for AMD signal regulatory pathways opening for these modalities.

That pipeline translates directly into trial volume. GlobalData recorded 47 Phase 1, 142 Phase 2, 90 Phase 3, and 54 Phase 4 ophthalmic trials initiated in 2023. Each trial carries ophthalmology-specific complexity: intravitreal injection endpoints, ocular imaging biomarkers, visual acuity scoring under standardized lighting, and safety monitoring for intraocular inflammation and pressure spikes. The dominant delivery route (topical eye drops at 41.8% share and 57% for the broader topical segment) is itself under pressure. Patient non-adherence to frequent intravitreal injections drives development of sustained-release implants, nanoparticles, liposomes, contact lens delivery, ocular inserts, in situ gels, and non-corneal diffusion routes. Each novel delivery system requires bespoke trial designs, specialized site training, and regulatory strategies that generalist CROs struggle to provide.

Major pharma moves confirm the capital commitment. Pfizer acquired Biotech Vision in March 2024. Roche launched VisioCure in April 2024 and secured European approval for Vabysmo's prefilled syringe in December 2024. Bayer acquired Ophthotech in May 2024. Teva partnered with Klinge Biopharma and Formycon in February 2025 to commercialize FYB203, a biosimilar to Eylea, across Europe and Israel. Frost & Sullivan notes these dynamics attract tier 1 biopharma, non-profits, and R&D consortia, all of whom need ophthalmology-savvy clinical operations.

Underpinning the biology, AI-driven drug discovery is accelerating candidate generation. The convergence of multiomic data (genome sequencing now under $1,000 and same-day), generative AI designing antibodies to novel targets, and scale of compute is producing candidates faster than clinical capacity can absorb. The failure rate, with over 80% of drugs entering trials failing, makes efficient trial execution a strategic lever. Ora's open roles in clinical operations and regulatory compliance map directly to this bottleneck: the market is not just producing more trials; it is producing more complex trials in a therapeutic area where generic CRO expertise is insufficient.

How Ora Differs From the Generalist CRO Model

Biotech startups and large contract research organizations hire for different mindsets. BioSpace reported that biotech employees "drive the bus": they make principal decisions on study design, indication selection, and resource allocation, often with tight budgets that expose anyone who cannot "roll their sleeves up" quickly. CRO staff, by contrast, provide input across hundreds of programs; they gain variety and stability because no single clinical readout determines the company's survival.

The three biggest global CROs (Parexel, IQVIA, and ICON) illustrate the breadth model. PharmaDailyJob's 2026 guide notes they support trials across oncology, rare disease, metabolic disorders, and more, while layering on healthcare analytics, artificial intelligence, and real-world evidence. Their job postings typically ask for experience managing multi-indication portfolios, fluency with decentralized trial platforms, and the ability to switch therapeutic areas every few months.

Ora flips that script. The company's own site states it has spent "over 50 years" conducting only ophthalmology trials, and its current openings cluster in clinical operations and regulatory compliance for eye-specific drugs and devices. Spherical Insights' figures put the global ophthalmology CRO market at $118.08 billion by 2035, up from $52.17 billion in 2024, a 7.71% CAGR driven by rising ocular disease rates and the push for economical, specialized trials. That growth creates a hiring filter: you need hands-on experience with ophthalmic endpoints (visual acuity scoring, intraocular pressure monitoring, retinal imaging workflows) and with FDA/EMA guidance documents that apply only to ocular products.

Iris Pharma, another pure-play ophthalmology CRO, markets the same niche; its leadership team is built from former academic retina specialists and former FDA ophthalmology reviewers. Ora's job descriptions mirror that profile, demanding ophthalmic clinical trial experience as a core requirement.

For job seekers, the contrast is practical. If you have spent five years running cardiovascular studies at a top-tier CRO, you bring operational rigor but zero domain fluency; Ora will likely pass. If you have two years coordinating a Phase II dry-eye study at an academic center, you speak the language of slit-lamp endpoints and corneal staining scales, and you clear the first hurdle. The niche is narrow, but the market data suggests it will stay tight for years. Candidates who invest in ophthalmology-specific regulatory training now position themselves for a segment that is growing faster than the broader CRO average.

What the Screen Actually Filters For

Ora's job postings read like a checklist for a very specific kind of clinical professional, and that is deliberate. The open roles span clinical research coordination, project management, and site contract administration, but the screening criteria converge on three non-negotiables: ophthalmic credentials, willingness to travel at a pace that would burn out most CRO veterans, and documented alignment with a values framework the company treats as operational doctrine.

Start with the hard requirements. A bachelor's degree in life sciences substitutes for one year in a clinical setting, but the preference language is revealing. Previous research coordinator experience is "strongly preferred." So are Certified Ophthalmic Associate (COA) or Certified Ophthalmic Technician (COT) certifications. Medical credentials such as certified phlebotomy technician (CPT) or emergency medical technician (EMT) certification are also listed as preferred. These are not generic biotech checkboxes. They signal that Ora needs people who can walk into a retinal specialist's office, speak the language, and execute protocol-specific procedures without a six-month ramp.

Then comes the travel requirement, stated without ambiguity: willingness to travel domestically up to 90 percent of the time, including back-to-back trips and weekends. That single line filters more candidates than any degree requirement. A per-diem clinical research coordinator role posted on OpenToWorkRemote carries the same demand: flexible schedule, weekend availability, domestic travel as needed. The Site Contract and Payment Associate role, by contrast, centers on contract negotiation and budget management with sponsors and investigative sites, suggesting a lower travel cadence but higher regulatory fluency. Ora's 400-person global footprint across North America, Europe, Asia, and Latin America means the travel burden is real, not theoretical.

Values alignment functions as a second filter. Ora publishes four core values (prioritizing kindness, operational excellence, cultivating joy, scientific rigor) and expects candidates to demonstrate "clear and sustained" embodiment of the linked behaviors. The careers page frames this explicitly: "We are actively seeking candidates who align with our core values... As you reflect on your fit for the role, consider how you resonate with these values." The competency model breaks down further: Execution Excellence (goal-setting, structure, focused collaborative delivery), IQ/EQ/SQ (agile positive thinking, growth mindset, authenticity, transparency, resilience, empathy, scientific and social curiosity), and radical candor in communication and conflict resolution. The purpose statement ("seek meaning and purpose and a desire to be part of something bigger than yourself") reads like a cultural shibboleth. In practice, it screens for people who will stay through the travel grind because they believe the work matters.

The interview process reflects this layering: application, recruiter screening, manager interview, team interview, offer. Feedback after the preliminary stage is not guaranteed. The company targets a hiring decision within two weeks of the final interview. Employee testimonials on the careers page (a Clinical Project Manager promoted to Senior CPM then department lead, a CRC I advancing to Clinical Trial Associate II in six years, a one-year hire citing travel and diversity as retention drivers) suggest the screen works. People who pass it tend to stay.

Compared with general biotech CROs, Ora's screen is narrower and deeper. A typical pharma CRO hires for therapeutic-area-agnostic project management, then trains indication specifics. Ora hires for ophthalmic fluency first, then layers project management on top. The COA/COT preference, the phlebotomy/EMT preference, and the 90-percent travel mandate are not industry-standard. They are the signature of a company that has supported 85-plus product approvals in 45 years by sending specialized teams to sites that run eye trials differently than oncology or cardiology sites. Candidates who show up with generic GCP training and no ophthalmic certifications are not competitive. The screen is designed to keep them out.

What Candidates Say About the Process

Glassdoor data shows 26 interview reviews and 26 interview questions posted anonymously for "Ora" across U.S., U.K., and India portals, a modest footprint that suggests candidates are engaging but not flooding the zone. Clinical Trial Associate professionals rate compensation and benefits at 3 out of 5 stars based on 73 reviews, matching the company-wide average. That middling score signals neither a pay premium nor a discount; it reads like a market-rate offer in a niche where specialized ophthalmology experience is the real currency.

The name collision doesn't help. Search "ORA interview" and you hit three distinct entities: the Office of Personnel Management's Online Retirement Application, the ophthalmic CRO this article covers, and Oura the smart-ring maker, which alone has 321 interview reviews on Glassdoor. That ambiguity raises the barrier for applicants who must self-filter before they even apply.

The barrier is real. Ora's open roles (heavy on clinical operations, regulatory compliance, and trial management) demand fluency in FDA guidance for ophthalmic endpoints, experience with reading-center workflows, and a track record managing multi-site Phase II/III trials in retinal or glaucoma indications. General biotech CRO veterans often lack the disease-area depth.

Appeal cuts the other way. For the subset who do have that niche (clinical research coordinators from academic retina departments, former sponsor medical monitors who ran AMD or diabetic retinopathy programs), Ora looks like a focused career step. The company's 45-year single-therapy-area track record means project variety stays within ophthalmology; you don't rotate into oncology or CNS. That specialization attracts people who want depth over breadth, and the hiring surge suggests the pipeline is full enough to sustain it.

Word-of-mouth in ophthalmic research circles (small, tight, conference-driven) carries more weight than Glassdoor. The market perceives Ora as a "specialist's specialist." That reputation narrows the funnel but improves yield: the candidates who clear the screen tend to stay. Turnover data isn't public, but the 3-star compensation rating combined with low review volume hints at a stable, if not vocal, workforce. For job seekers, the takeaway is binary: either you have the ophthalmic trial pedigree and the door opens, or you don't and it doesn't.

The Phase 3 record that opened this story (22 programs, zero failures) is not a legacy metric. It is the operating standard that every new hire in clinical operations and regulatory compliance will be measured against. The open roles are not growth for growth's sake. They are the next shift of specialists needed to keep that record intact as the pipeline swells with gene therapies, bispecifics, and delivery systems that have never been tested in human eyes. The screen is strict because the standard is strict. The travel is relentless because the sites are global. The values language is explicit because the alternative (burnout, drift, a missed endpoint) is not an option. Ora does not hire for potential. It hires for the pedigree that has already held the line.

Working in frontier tech? Zero G Talent tracks the openings: see every open ASML role, browse frontier tech jobs, openings at Stripe, and the people building the field.